Edition:
United States

Karyopharm Therapeutics Inc (KPTI.OQ)

KPTI.OQ on NASDAQ Stock Exchange Global Select Market

11.97USD
4:00pm EDT
Change (% chg)

$0.66 (+5.84%)
Prev Close
$11.31
Open
$11.33
Day's High
$12.48
Day's Low
$11.25
Volume
112,716
Avg. Vol
81,949
52-wk High
$14.63
52-wk Low
$6.27

Latest Key Developments (Source: Significant Developments)

Karyopharm reports Q4 loss of $0.65 per share
Thursday, 16 Mar 2017 07:30am EDT 

Karyopharm Therapeutics Inc : Karyopharm reports fourth quarter and full year 2016 financial results and provides Selinexor clinical update . For quarter, research and development expense was $20.7 million compared to $24.1 million for quarter ended December 31, 2015 . Net loss $0.65 per share for quarter ended December 31, 2016 . Expects operating cash burn for year ending December 31, 2017 to be in range of $85 to 90 million . Says expects to commence Boston study in early 2017 . Expects that existing cash and cash equivalents will fund its research and development programs and operations until end of 2018 .SDD ARM of Stomp study expected to enroll about 44 patients and Co expects to report top-line data in late 2017 or early 2018.  Full Article

Karyopharm to pause enrollment in Selinexor trials
Friday, 10 Mar 2017 07:55pm EST 

Karyopharm Therapeutics Inc : Karyopharm announces partial clinical hold to pause enrollment in Selinexor trials . All currently enrolled patients with stable disease or better can continue receiving selinexor . Company has amended investigator's brochure and informed consent documents as requested by fda . Expects timelines for both ongoing and planned studies to remain materially unchanged . Karyopharm Therapeutics- received written notice from u.s. Fda that its clinical trials for selinexor have been placed on partial clinical hold . Karyopharm Therapeutics- fda has indicated partial clinical hold is due to incomplete information in existing version of investigator's brochure . Karyopharm Therapeutics - partial clinical hold is not result of any patient death or any new information regarding safety profile of selinexor . Karyopharm Therapeutics inc - as of march 10, co had provided all requested materials to fda believed to be required to lift partial clinical hold .Karyopharm Therapeutics says co believes its previously disclosed enrollment rates and timelines for its ongoing trials will remain materially unchanged.  Full Article

Karyopharm Therapeutics files for common stock offering
Tuesday, 8 Nov 2016 06:30am EST 

Karyopharm Therapeutics Inc : Karyopharm Therapeutics Inc - Files for common stock offering of up to $50 million - SEC filnig Source: (http://bit.ly/2fAET3z) Further company coverage: [KPTI.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Wellington Management Group Llp reports 11.83 pct passive stake in Karyopharm
Tuesday, 11 Oct 2016 12:51pm EDT 

:Wellington Management Group Llp reports passive stake of 11.83 percent in Karyopharm Therapeutics Inc as of Sept 30 - SEC Filing.  Full Article

Karyopharm Therapeutics provides update on Phase 2b STORM study
Tuesday, 30 Aug 2016 12:14pm EDT 

Karyopharm Therapeutics Inc : Intends to expand its Phase 2b storm study evaluating activity of selinexor in multiple myeloma .Intends to expand its Phase 2b storm study to include approximately 120 additional patients with penta-refractory MM.  Full Article

Karyopharm reports Q2 loss per share $0.84
Thursday, 4 Aug 2016 07:30am EDT 

Karyopharm Therapeutics Inc : Q2 loss per share $0.84 .Q2 earnings per share view $-0.76 -- Thomson Reuters I/B/E/S.  Full Article

Karyopharm says initiates phase 1 clinical trial with KPT-9274
Wednesday, 22 Jun 2016 07:30am EDT 

Karyopharm : Says first-In-Human, multi-center, open-label, dose-escalation trial is expected to enroll up to 175 patients .Says initiates Phase 1 Clinical Trial With Kpt-9274.  Full Article

Karyopharm Q1 loss per share $0.75
Monday, 9 May 2016 07:30am EDT 

Karyopharm Therapeutics Inc : Expects existing cash and cash equivalents will fund research and development programs and operations into middle of 2018 . Expects to end 2016 with at least $120 million in cash, cash equivalents and investments . Karyopharm reports first quarter 2016 financial results and highlights recent progress . Q1 loss per share $0.75 .Q1 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Karyopharm Therapeutics presents positive clinical data for selinexor (kpt-330)
Monday, 15 Jun 2015 07:00am EDT 

Karyopharm Therapeutics:Says presentation of positive clinical data for its lead product candidate, selinexor (kpt-330).Selinexor demonstrated a 43% overall response rate (partial response or better) in patients on study greater than one month.Median overall survival and progression free survival were 4.6 months and 1.7 months, respectively, for the entire study.Adverse events manageable with standard supportive care and clinically significant cumulative toxicities were not observed.  Full Article

Karyopharm Therapeutics initiates STORM clinical trial of Oral Selinexor (KPT-330) in Multiple Myeloma
Thursday, 28 May 2015 08:00am EDT 

Karyopharm Therapeutics:Initiates the STORM study (SelinexorTreatment ofRefractoryMyeloma).STORM is a multi-center, single-arm Phase 2 study of selinexor (KPT-330) in heavily-pretreated patients with quad-refractory multiple myeloma.  Full Article

More From Around the Web

BRIEF-Karyopharm reports Q4 loss of $0.65 per share

* Karyopharm reports fourth quarter and full year 2016 financial results and provides Selinexor clinical update